RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $35.

December 14, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst reaffirms an Outperform rating on VRDN with a $35 price target, indicating a positive outlook for the stock.
The reiteration of an Outperform rating by a prominent analyst like Gregory Renza suggests a bullish stance on VRDN's stock. The maintained price target of $35 implies a potential upside from the current trading price, which could positively influence investor sentiment and the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100